Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

64
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
64
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

83
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
83
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

51
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
51
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

50
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
50

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes.

Biometrics·2026
Same author

A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimization.

Statistical methods in medical research·2026
Same author

Sex-specific association between metabolic score for insulin resistance and mortality in incident peritoneal dialysis patients.

Renal failure·2026
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Neuro-oncology advances·2026
Same author

Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
查看所有相关文章

相关实验视频

Updated: Jun 13, 2025

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K

一个贝叶斯潜伏子组平台设计,用于剂量优化.

Rongji Mu1, Xiaojiang Zhan2, Rui Sammi Tang2

  • 1Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Biometrics
|September 10, 2024
PubMed
概括
此摘要是机器生成的。

项目Optimus将瘤药物开发从最大耐受剂量转移到最佳生物剂量 (OBD). 一个新的主协议平台试验设计有效地识别了跨多种癌症类型的新药和组合的OBD.

关键词:
贝叶斯适应式设计是贝叶斯的适应式设计.潜伏子组是一个潜伏子组.最好的生物剂量是最佳的.试验平台 试验平台 试验平台

更多相关视频

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K
Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

598

相关实验视频

Last Updated: Jun 13, 2025

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K
Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

598

科学领域:

  • 在瘤学瘤学.
  • 临床试验设计 临床试验设计
  • 生物统计学 生物统计学

背景情况:

  • 美国FDA的项目Optimus旨在改革瘤药物开发中的剂量优化.
  • 该倡议促进从最大耐受剂量 (MTD) 转向最佳生物剂量 (OBD).

研究的目的:

  • 提出基于主协议的平台试验设计,用于同时识别新药的OBD.
  • 为了评估新药组合与护理标准或其他药物在多种适应症.

主要方法:

  • 利用贝叶斯潜伏子组模型来解决各种适用症治疗异质性.
  • 采用贝叶斯的层次模型,在子组内借用信息.
  • 纳入临时分析以更新子组成员资格,剂量毒性/有效性估计和风险-收益效用.

主要成果:

  • 拟议的设计在模拟研究中证明了可取的操作特性.
  • 它提供了一种灵活有效的方法来优化在瘤药物开发中的剂量.
  • 设计方便了对剂量升级/降级作出明智的,特定于手臂的决策.

结论:

  • 主协议平台试验设计有效地确定药物组合的最佳生物剂量.
  • 这种方法有可能缩短药物开发时间表并降低成本.
  • 设计可以通过简化开发过程来加速监管批准.